Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation

Annals of Medicine

Volumn 45, Issue 2, 2013, Pages 162-170

  Venojärvi, Mika ^a,f   Wasenius, Niko ^b   Manderoos, Sirpa ^b,f   Heinonen, Olli J ^c   Hernelahti, Miika ^c   Lindholm, Harri ^d   Surakka, Jukka ^e   Lindström, Jaana ^f   Aunola, Sirkka ^f   Atalay, Mustafa ^a   Eriksson, Johan G ^b,f,g,h  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^e ARCADA UNIVERSITY OF APPLIED SCIENCES   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g FOLKHÄLSAN RESEARCH CENTER   (Finland)

^h VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

Chemerin; Impaired glucose regulation; Nordic walking; Resistance training

Indexed keywords

CHEMERIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; BODY COMPOSITION; BODY FAT; BUILDING INDUSTRY; CARBOHYDRATE INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FAT BODY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LEISURE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NORDIC WALKING; OCCUPATION; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WALKING; WORKLOAD;

ADULT; AGED; BLOOD GLUCOSE; CHEMOKINES; EXERCISE; HUMANS; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS; WALKING;

EID: 84873372246     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.727020     Document Type: Review

References (61)

1. Tonjes A, Fasshauer M, Kratzsch J, Stumvoll M, Bluher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One. 2010; 5: e13911.
2. Sell H, Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc. 2009; 68: 378-84.
3. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases aft er weight loss induced by bariatric surgery. JClin Endocrinol Metab. 2010; 95: 2892-6.
4. Hopps E, Canino B, Caimi G. Effects of exercise on inflammation markers in type 2 diabetic subjects. Acta Diabetol. 2011; 48: 183-9.
5. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006; 55: 2688-97.
6. Nieto-Vazquez I, Fern á ndez-Veledo S, de Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes. 2008; 57: 3211-21.
7. Hamed EA, Zakary MM, Ahmed NS, Gamal RM. Circulating leptin and insulin in obese patients with and without type 2 diabetes mellitus: relation to ghrelin and oxidative stress. Diabetes Res Clin Pract. 2011; 94: 434-41.
8. Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010; 299: E506-15.
9. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010; 45: 235-42.
10. Becker M, Rabe K, Lebherz C, Zugwurst J, Goke B, Parhofer KG, et al. Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes. 2010; 59: 2898-903.
11. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. JClin Endocrinol Metab. 2009; 94: 3085-8.
12. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, et al. Chemerin is associated with markers of infl ammation and components of the metabolic syndrome but does not predict coronary atherosclerosis . Eur J Endocrinol. 2009; 161: 339-44.
13. Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. JInvestig Med. 2010; 58: 883-6.
14. Xu D, Huang XD, Yuan JP, Wu J, Fan Y, Luo HS, et al. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD. Hepatogastroenterology. 2011; 58: 1703-7.
15. Strasser B, Siebert U, Schobersberger W. Resistance training in the treatment of the metabolic syndrome: a systematic review and metaanalysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Med. 2010; 40: 397-415.
16. Flack KD, Davy KP, Hulver MW, Winett RA, Frisard MI, Davy BM. Aging, resistance training, and diabetes prevention. JAging Res. 2010; 2011: 127315.
17. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, et al. The anti-infl ammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil. 2007; 14: 837-43.
18. You T, Nicklas BJ. Chronic infl ammation: role of adipose tissue and modulation by weight loss. Curr Diabetes Rev. 2006; 2: 29-37.
19. Sixt S, Beer S, Bluher M, KorffN, Peschel T, Sonnabend M, et al. Long-but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. Eur Heart J. 2010; 31: 112-9.
20. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, Loeser RF, et al. Diet-induced weight loss, exercise, and chronic infl ammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr. 2004; 79: 544-51.
21. Andersson J, Jansson JH, Hellsten G, Nilsson TK, Hallmans G, Boman K. Effects of heavy endurance physical exercise on infl ammatory markers in non-athletes. Atherosclerosis. 2010; 209: 601-5.
22. Jones NL. Clinical exercise testing. 3 rd ed. Philadelphia: WB Saunder s; 1988.
23. McDonagh M JN, D avies C TM. Adaptive response of mammalian skeletal muscle to exercise with high loads. Eur J Appl Occup Physiol. 1984; 52: 139-55.
24. Laukkanen RM, Kukkonen-Harjula TK, Oja P, Pasanen ME, Vuori IM. Prediction of change in maximal aerobic power by the 2-km walk test aft er walking training in middle-aged adults. Int J Sports Med. 2000; 21: 113-6.
25. Lehtonen HM, Suomela JP, Tahvonen R, Vaarno J, Venojarvi M, Viikari J, et al. Berry meals and risk factors associated with metabolic syndrome. Eur J Clin Nutr. 2010; 64: 614-21.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
27. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33.
28. Laatikainen T, Tapanainen H, Alft han G, Salminen I, Sundvall J, LeiviskäJ, et al. Tutkimuksen toteutus ja tulokset I.Helsinki: Publications of the National Public Health Institute; 2007: B7.
29. Haapa E, Toponen T, Pietinen P, Rasanen L. Annoskuvakirja. Helsinki: Painokaari Oy; 1985 [in Finnish].
30. Pietinen P, H artman A M, H aapa E, R asanen L, H aapakoski J, Palmgren J, et al. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am J Epidemiol. 1988; 128: 655-66.
31. Ovaskainen ML, Valsta LM, Lauronen J. The compilation of food analysis values as a database for dietary studies-the Finnish experience. Food Chem. 1996; 57: 133-6.
32. Ernst MC, Sinal CJ. Chemerin: at the crossroads of infl ammation and obesity. Trends Endocrinol Metab. 2010; 21: 660-7.
33. Bondue B, W ittamer V, P armentier M. Chemerin and its receptors in leukocyte trafficking, infl ammation and metabolism. Cytokine Growth Factor Rev. 2011; 22: 331-8.
34. Weigert J, N eumeier M, W anninger J, F ilarsky M, B auer S, W iest R, et a l. Systemic chemerin is related to infl ammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010; 72: 342-8.
35. Lofgren P, Andersson I, Adolfsson B, Leijonhufvud BM, Hertel K, Hoffstedt J, et al. Long-term prospective and controlled studies demonstrate adipose tissue hypercellularity and relative leptin deficiency in the postobese state. JClin Endocrinol Metab. 2005; 90: 6207-13.
36. Mlinar B, Marc J. Review: new insights into adipose tissue dysfunction in insulin resistance. Clin Chem Lab Med. 2011; 49: 1925-35.
37. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. JClin Endocrinol Metab. 2007; 92: 1023-33.
38. Klempel MC, Varady KA. Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. Nutr Rev. 2011; 69: 145-54.
39. Kotnik P, F ischer-Posovszky P, W abitsch M. R BP4: a controversial adipokine. Eur J Endocrinol. 2011; 165: 703-11.
40. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. NEngl J Med. 2006; 354: 2552-63.
41. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005; 54: 603-8.
42. Haus J M, S olomon T P, M archetti C M, E dmison J M, G onzalez F, Kirwan JP. Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. JClin Endocrinol Metab. 2010; 95: 323-7.
43. Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RA. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol. 2008; 45: 147-50.
44. Faerch K, B orch-Johnsen K, H olst J J, V aag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009; 52: 1714-23.
45. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006; 55: 1430-5.
46. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005; 42: 987-1000.
47. Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). JGastrointestin Liver Dis. 2011; 20: 153-9.
48. Lin J, Zhang M, Song F, Qin J, Wang R, Yao P, et al. Association between C-reactive protein and pre-diabetic status in a Chinese Han clinical population. Diabetes Metab Res Rev. 2009; 25: 219-3.
49. Sun J, Ren J, Pang ZC, Gao WG, Nan HR, Wang SJ, et al. The association of gamma-glutamyltransferase and C-reactive protein with IFG/IGT in Chinese adults in Qingdao, China. Clin Chim Acta. 2011; 412: 1658-61.
50. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137: 865-72.
51. Gastaldelli A, K ozakova M, H lund K, F lyvbjerg A, F avuzzi A, Mitrakou A, et al.; RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009; 49: 1537-44.
52. Bremer AA, Devaraj S, Afi fy A, Jialal I. adipose tissue dysregulation in patients with metabolic syndrome. JClin Endocrinol Metab. 2011; 96: E1782-8.
53. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab. 2010; 21: 345-52.
54. Klimcakova E, Polak J, Moro C, Hejnova J, Majercik M, Viguerie N, et al. Dynamic strength training improves insulin sensitivity without altering plasma levels and gene expression of adipokines in subcutaneous adipose tissue in obese men. JClin Endocrinol Metab. 2006; 91: 5107-12.
55. Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, et al. Effect of lifestyle modifi cation on adipokine levels in obese subjects with insulin resistance. Obes Res. 2003; 11: 1048-54.
56. Gram B, Christensen R, Christiansen C, Gram J. Effects of Nordic walking and exercise in type 2 diabetes mellitus: a randomized controlled trial. Clin J Sport Med. 2010; 20: 355-61.
57. Gualano B, DE Salles Painneli V, Roschel H, Artioli GG, Neves M Jr, De Sa Pinto AL, et al. Creatine in type 2 diabetes: a randomized, doubleblind, placebo-controlled trial. Med Sci Sports Exerc. 2011; 43: 770-8.
58. Kelley GA, Kelley KS, Roberts S, Haskell W. Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. BMC Med. 2011; 9: 74.
59. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002; 288: 1882-8.
60. Strasser B, S chobersberger W. Evidence for resistance training as a treatment therapy in obesity. J Obes. 2011;2011. pii:482564.
61. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fi tness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011; 43: 1334-59.